Evercore Maintains Charles River(CRL.US) With Buy Rating, Maintains Target Price $225
Evercore ISI Sticks to Their Buy Rating for Charles River Labs (CRL)
Charles River Labs Is Maintained at Neutral by Baird
Charles River Analyst Ratings
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating, Announces Target Price $210
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating
Hold Rating on Charles River Labs Amidst Pharma Restructuring and Uncertain Near-Term Earnings
Mizuho Adjusts Price Target on Charles River Laboratories International to $210 From $235, Maintains Neutral Rating
Charles River Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Charles River Labs (CRL) and Akero Therapeutics (AKRO)
Charles River Analyst Ratings
Baird Cuts Charles River Labs to Neutral, Cites Lagging Recovery
Morgan Stanley Cuts Price Target on Charles River Laboratories International to $215 From $235
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Rani Therapeutics Holdings (RANI) and Charles River Labs (CRL)
Barclays Keeps Their Hold Rating on Charles River Labs (CRL)
Charles River Labs Price Target Cut to $191.00/Share From $239.00 by Baird
Charles River Analyst Ratings
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $240 From $300
Stephens Adjusts Price Target on Charles River Laboratories International to $250 From $280
Charles River Analyst Ratings